Clostridium difficile clinical isolates exhibit variable susceptibility and proteome alterations upon exposure to mammalian cationic antimicrobial peptides

Anaerobe

Volumn 18, Issue 6, 2012, Pages 614-620

  McQuade, Rebecca ^a   Roxas, Bryan ^a   Viswanathan, V K ^a,b   Vedantam, Gayatri ^a,b,c  

^a Department of Veterinary Science and Microbiology ^*  (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

Antimicrobial peptide; Antimicrobial susceptibility; Bacterial colonization; Cathelicidin; Clostridium difficile; Innate immunity; LL 37

Indexed keywords

ABC TRANSPORTER; BACTERIAL PROTEIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CELL WALL BIOSYNTHESIS PROTEIN; LYSINE; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEOME; SMAP 29 PEPTIDE; SURFACE LAYER PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DRUG EXPOSURE; HOSPITAL INFECTION; IMMUNE EVASION; INCIDENCE; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; RECURRENT INFECTION; RIBOTYPING; UNITED STATES;

ANTIMICROBIAL CATIONIC PEPTIDES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; IMMUNE EVASION; MICROBIAL SENSITIVITY TESTS; PROTEOME; UNITED STATES;

BACTERIA (MICROORGANISMS); CLOSTRIDIUM DIFFICILE; MAMMALIA;

EID: 84870312026     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2012.09.004     Document Type: Article

References (34)

1. Cohen S.H., Gerding D.N., Johnson S., Kelly C.P., Loo V.G., McDonald L.C., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infection Control & Hospital Epidemiology 2010, 31:431-455.
2. Vedantam G, Clark A, Chu M, McQuade R, Mallozzi M, Viswanathan VK. Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response. Gut Microbes;3:121-34.
3. Dubberke E.R., Wertheimer A.I. Review of current literature on the economic burden of Clostridium difficile infection. Infection Control & Hospital Epidemiology 2009, 30:57-66.
4. Merrigan M., Venugopal A., Mallozzi M., Roxas B., Viswanathan V.K., Johnson S., et al. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. Journal of Bacteriology 2010, 192:4904-4911.
5. Burns D.A., Heeg D., Cartman S.T., Minton N.P. Reconsidering the sporulation characteristics of hypervirulent Clostridium difficile BI/NAP1/027. PloS One 2011, 6:e24894.
6. Bucki R., Leszczynska K., Namiot A., Sokolowski W. Cathelicidin LL-37: a multitask antimicrobial peptide. Archivum Immunologiae et Therapiae Experimentalis (Warsz) 2010, 58:15-25.
7. Leszczynska K., Namiot A., Fein D.E., Wen Q., Namiot Z., Savage P.B., et al. Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice. BMC Microbiology 2009, 9:187.
8. Durr U.H., Sudheendra U.S., Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochimica Et Biophysica Acta 2006, 1758:1408-1425.
9. Hase K., Eckmann L., Leopard J.D., Varki N., Kagnoff M.F. Cell differentiation is a key determinant of cathelicidin LL-37/human cationic antimicrobial protein 18 expression by human colon epithelium. Infection and Immunity 2002, 70:953-963.
10. Tollin M., Bergman P., Svenberg T., Jornvall H., Gudmundsson G.H., Agerberth B. Antimicrobial peptides in the first line defence of human colon mucosa. Peptides 2003, 24:523-530.
11. McBride S.M., Sonenshein A.L. The dlt operon confers resistance to cationic antimicrobial peptides in Clostridium difficile. Microbiology 2011, 157:1457-1465.
12. Arzese A., Skerlavaj B., Tomasinsig L., Gennaro R., Zanetti M. Antimicrobial activity of SMAP-29 against the Bacteroides fragilis group and clostridia. Journal of Antimicrobial Chemotherapy 2003, 52:375-381.
13. Peschel A., Sahl H.G. The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nature Reviews Microbiology 2006, 4:529-536.
14. Li M., Cha D.J., Lai Y., Villaruz A.E., Sturdevant D.E., Otto M. The antimicrobial peptide-sensing system aps of Staphylococcus aureus. Molecular Microbiology 2007, 66:1136-1147.
15. Majchrzykiewicz J.A., Kuipers O.P., Bijlsma J.J. Generic and specific adaptive responses of Streptococcus pneumoniae to challenge with three distinct antimicrobial peptides, bacitracin, LL-37, and nisin. Antimicrobial Agents and Chemotherapy 2010, 54:440-451.
16. McBride S.M., Sonenshein A.L. Identification of a genetic locus responsible for antimicrobial peptide resistance in Clostridium difficile. Infection and Immunity 2011, 79:167-176.
17. Standards NCfCL Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically 2003, Wayne, PA. 6th ed.
18. Dean SN, Bishop BM, van Hoek ML. Susceptibility of Pseudomonas aeruginosa biofilm to alpha-helical peptides: D-enantiomer of LL-37. Front Microbiology;2:128.
19. Dean SN, Bishop BM, van Hoek ML. Natural and synthetic cathelicidin peptides with anti-microbial and anti-biofilm activity against Staphylococcus aureus. BMC Microbiology;11:114.
20. Monot M., Boursaux-Eude C., Thibonnier M., Vallenet D., Moszer I., Medigue C., et al. Reannotation of the genome sequence of Clostridium difficile strain 630. J Med Microbiol 2011, 60:1193-1199.
21. Sebaihia M., Wren B.W., Mullany P., Fairweather N.F., Minton N., Stabler R., et al. The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nature Genetics 2006, 38:779-786.
22. Pietiainen M., Francois P., Hyyrylainen H.L., Tangomo M., Sass V., Sahl H.G., et al. Transcriptome analysis of the responses of Staphylococcus aureus to antimicrobial peptides and characterization of the roles of vraDE and vraSR in antimicrobial resistance. BMC Genomics 2009, 10:429.
23. Brodsky I.E., Ghori N., Falkow S., Monack D. Mig-14 is an inner membrane-associated protein that promotes Salmonella typhimurium resistance to CRAMP, survival within activated macrophages and persistent infection. Molecular Microbiology 2005, 55:954-972.
24. Poyart C., Pellegrini E., Marceau M., Baptista M., Jaubert F., Lamy M.C., et al. Attenuated virulence of Streptococcus agalactiae deficient in D-alanyl-lipoteichoic acid is due to an increased susceptibility to defensins and phagocytic cells. Molecular Microbiology 2003, 49:1615-1625.
25. Jain S., Graham C., Graham R.L., McMullan G., Ternan N.G. Quantitative proteomic analysis of the heat stress response in Clostridium difficile strain 630. Journal of Proteome Research 2011, 10:3880-3890.
26. Peschel A., Otto M., Jack R.W., Kalbacher H., Jung G., Gotz F. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. The Journal of Biological Chemistry 1999, 274:8405-8410.
27. Peltier J., Courtin P., El Meouche I., Lemee L., Chapot-Chartier M.P., Pons J.L. Clostridium difficile has an original peptidoglycan structure with a high level of N-acetylglucosamine deacetylation and mainly 3-3 cross-links. The Journal of Biological Chemistry 2011, 286:29053-29062.
28. Samant S., Hsu F.F., Neyfakh A.A., Lee H. The Bacillus anthracis protein MprF is required for synthesis of lysylphosphatidylglycerols and for resistance to cationic antimicrobial peptides. Journal of Bacteriology 2009, 191:1311-1319.
29. Roy H., Ibba M. RNA-dependent lipid remodeling by bacterial multiple peptide resistance factors. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:4667-4672.
30. Calabi E., Ward S., Wren B., Paxton T., Panico M., Morris H., et al. Molecular characterization of the surface layer proteins from Clostridium difficile. Molecular Microbiology 2001, 40:1187-1199.
31. de la Riva L., Willing S.E., Tate E.W., Fairweather N.F. Roles of cysteine proteases Cwp84 and Cwp13 in biogenesis of the cell wall of Clostridium difficile. Journal of Bacteriology 2011, 193:3276-3285.
32. Pietiainen M., Gardemeister M., Mecklin M., Leskela S., Sarvas M., Kontinen V.P. Cationic antimicrobial peptides elicit a complex stress response in Bacillus subtilis that involves ECF-type sigma factors and two-component signal transduction systems. Microbiology 2005, 151:1577-1592.
33. Cordone A., Lucchini S., De Felice M., Ricca E. Direct and indirect control of Lrp on LEE pathogenicity genes of Citrobacter rodentium. FEMS Microbiology Letters 2011, 325:64-70.
34. Lin W., Kovacikova G., Skorupski K. The quorum sensing regulator HapR downregulates the expression of the virulence gene transcription factor AphA in Vibrio cholerae by antagonizing Lrp- and VpsR-mediated activation. Molecular Microbiology 2007, 64:953-967.